Latest News for HLCO
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases…
Company Begins Executing Revenue Generation Strategy through First Commercial Product Launch New York, NY – Aug. 11, 2026 – TheNewswire – Synbio International, Inc. (OTC: SYIN) today marks a significant milestone in its evolution. After an extended period focused on corporate restructuring, strategic partnerships, and business development, the Company is now entering commercial operations with the launch of its…
AI is entering a radical new phase that goes above and beyond generative AI and chatbots.
Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers Allowed claims directly support the Company's ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HLCO.
U.S. House Trading
No House trades found for HLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.